AIVITA Biomedical develops personalized vaccines using a pan-antigenic approach that targets all neoantigens to effectively address cancer's mutation challenges. Their autologous cell therapy platform also produces a multi-pathogen vaccine kit, providing adaptive immunity against a range of infectious diseases.

Awakn Life Sciences is developing medication-assisted treatments (MATs) that target brain circuits associated with addiction, specifically focusing on Alcohol Use Disorder (AUD), which affects millions globally. Their evidence-based approach aims to improve treatment outcomes and reduce relapse rates by enabling patients to engage in psychotherapeutic processes that foster lasting behavioral change.

Ceretype Neuromedicine offers a next-generation fMRI brain biomarker platform that provides precise, millimeter-scale mapping of brain activity to enhance drug development and patient care in neuropsychiatry. By delivering actionable insights into brain circuitry, Ceretype addresses the lack of biological evidence in psychiatric treatment, enabling more effective and personalized therapeutic solutions.

Cybin develops tryptamine-based psychedelic therapeutics using proprietary drug discovery platforms and controllable drug delivery systems to treat mental health conditions such as Major Depressive Disorder and Generalized Anxiety Disorder. The company aims to provide safe and effective treatment options that address the unmet needs of patients suffering from these disorders.

Enthea operates as a third-party administrator specializing in employer-sponsored mental health benefits. The company integrates advanced, evidence-based therapies such as Ketamine-Assisted Therapy (KAT) and Stellate Ganglion Block (SGB) into existing benefits plans. This turnkey solution provides employees access to root-cause treatments, aiming for measurable ROI through reduced symptoms, lower claims, and improved retention.

Fluence provides continuing education and certification programs for mental health practitioners in psychedelic-assisted therapy and integration, utilizing evidence-based training methods developed by experienced clinicians and researchers. The organization addresses the lack of specialized training in the emerging field of psychedelic therapy, equipping professionals with the necessary skills to effectively support clients in their therapeutic journeys.

Gilgamesh Pharmaceuticals develops new chemical entities targeting the root causes of depression, anxiety, and stress-related disorders through advanced medicinal chemistry and an AI-powered discovery platform. Their therapies include rapid-acting, non-hallucinogenic neuroplastogens and safer ibogaine analogs, offering improved efficacy and safety profiles for patients.